WuXi TIDES Global Network

Oligonucleotide and peptide discovery: Delivering oligonucleotide and peptide medicinal chemistry solutions to global pharma and biotech customers for creating, identifying, and supporting the discovery of preclinical candidates (PCC’s) with our leading discovery chemistry platform.

Pre-formulation and formulation: Parenteral oligonucleotide and peptide drug preformulation and formulation development, lipid nanoparticle formulation development.

Oligonucleotide discovery: Delivering oligonucleotide medicinal chemistry solutions to global pharma and biotech customers for creating, identifying, and supporting the discovery of preclinical candidates (PCC’s) with our enabling discovery chemistry platform.

Amidite and GalNAc: One-stop solution including custom synthesis solutions for various amidite and GalNAc molecules, oligonucleotides, as well as a broad range of oligonucleotide-based conjugates. 300+ catalog amidite products are available to accelerate your oligonucleotide therapeutic development.

Delivering peptide medicinal chemistry solutions to global pharma and biotech customers for creating, identifying, and supporting the discovery of preclinical candidates (PCC’s) with our enabling discovery chemistry platform.

Providing custom synthesis solutions to global pharma and biotech customers for unnatural amino acids and other peptide related building blocks. 2,200+ catalog unnatural amino acid products are available to accelerate your peptide therapeutic development.

Changzhou is about 1-hour driving distance (75 km) to Wuxi city (drug product site) which enables seamless collaborations between API team and formulation team for efficient, flexible, and high-quality solutions to global pharma and biotech customers.

Oligonucleotide and peptide API process development and manufacturing: Changzhou site is a fully integrated R&D and manufacturing campus providing a unique one-site solution for APIs and advanced intermediates, including small molecule, HPAPI, oligonucleotide, peptide and related synthetic conjugates, through preclinical and clinical development to global commercial launch.

Changzhou site has successfully passed inspections by US FDA and China NMPA multiple times since 2018.

Wuxi city is about 1-hour driving distance (75 km) to Changzhou (Oligonucleotide and peptide API process R&D and manufacturing site) which enables seamless collaborations between API team and formulation team for efficient, flexible, and high-quality solutions to global pharma and biotech customers.

Formulation development and manufacturing: Parenteral oligonucleotide and peptide formulation development as well as analytical testing and QC platform. Parenteral formulation manufacturing lines feature a fully enclosed isolator supporting various of dosage forms including solution, emulsion, suspension and lyophilized powder with different filling format including vial, pre-filled syringe and cartridge.

Lipid nanoparticle formulation development and manufacturing: LNP platform features multi-channel mixing technology for robust scalability and reproducibility with integrated formulation development, analytical, in vitro/ in vivo evaluation. GMP manufacturing line is fully validated and in use.

Wuxi city site has successfully passed inspections by US FDA, EMA and China NMPA multiple times since 2021.

Coming Soon. With a total area of 170 acres, Taixing site is an API manufacturing site for small molecule, oligonucleotide, peptide and the complex conjugates. Phase I include a large-scale oligonucleotide and peptide production plant, expected to start operation by end of 2023.

Coming Soon. It is a new 50-acre API process R&D and manufacturing site in Singapore. Phase I includes a new large scale manufacturing plant for oligonucleotides, peptides and the related synthetic conjugates, expected to start operation in 2026.

Coming Soon. The phase I of this 190-acre new facility is designed for formulation development and manufacture including packaging, labelling and distribution for oral and parenteral drug products including oligonucleotides, peptides and the related synthetic conjugates, expected to start operation in 2026.